MSFLX
Price
$32.52
Change
-$0.71 (-2.14%)
Updated
Dec 18 closing price
RWIBX
Price
$62.66
Change
-$1.77 (-2.75%)
Updated
Dec 18 closing price
Ad is loading...

MSFLX vs RWIBX

Header iconMSFLX vs RWIBX Comparison
Open Charts MSFLX vs RWIBXBanner chart's image
Morgan Stanley Inst Global Franchise L
Price$32.52
Change-$0.71 (-2.14%)
VolumeN/A
CapitalizationN/A
American Funds Capital World Gr&Inc R2
Price$62.66
Change-$1.77 (-2.75%)
VolumeN/A
CapitalizationN/A
MSFLX vs RWIBX Comparison Chart
Loading...
View a ticker or compare two or three
VS
MSFLX vs. RWIBX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MSFLX is a Buy and RWIBX is a Buy.

FUNDAMENTALS
Fundamentals
RWIBX has more cash in the bank: 121B vs. MSFLX (2.85B). RWIBX pays higher dividends than MSFLX: RWIBX (1.05) vs MSFLX (0.17). MSFLX was incepted earlier than RWIBX: MSFLX (13 years) vs RWIBX (23 years). RWIBX is a more actively managed with annual turnover of: 27.00 vs. MSFLX (15.00). MSFLX has a lower initial minimum investment than RWIBX: MSFLX (0) vs RWIBX (250). MSFLX (11.74) and RWIBX (11.34) have marching annual gain over last year. MSFLX return over 5 years is better than : 35.19 vs. RWIBX (29.64).
MSFLXRWIBXMSFLX / RWIBX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence13 years23 years-
Gain YTD10.8359.781111%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets2.85B121B2%
Annual Yield % from dividends0.171.0516%
Returns for 1 year11.7411.34104%
Returns for 3 years6.388.4176%
Returns for 5 years35.1929.64119%
Returns for 10 years86.6644.22196%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LITM0.180.03
+17.46%
Snow Lake Resources Ltd
NUVB2.810.12
+4.46%
Nuvation Bio
ENTG109.362.65
+2.48%
Entegris
ARQ7.01-0.04
-0.57%
Arq
PTCT47.02-1.59
-3.27%
PTC Therapeutics